Project Grant F32AI197623
Award Date 10/10/26
Completion Date 6/30/27
Dollars Obligated $154K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $274,991 on May 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacterial membrane fusion sustains commensal resilience during enteric pathogen infection. The research examines molecular mechanisms by which commensal bacteria in the human gut withstand or recover from perturbations caused by enteric infections, particularly how Bacteroides...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University $105,216 on December 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of lipid-laden macrophages in Staphylococcus aureus osteomyelitis abscess formation. The research employs multimodal imaging techniques, including matrix-assisted laser desorption/ionization imaging mass spectrometry, to examine the spatial localization and physiology of...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded Vanderbilt University $100,228.00 on December 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a Project Grant to investigate how intracellular Pseudomonas aeruginosa exploits host fatty acid metabolism during urinary tract infections. The funded research will identify mechanisms by which P. aeruginosa hijacks host fatty acid...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $3.252 million on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to generate pre-IND validation data for novel bacterial metabolism inhibitors targeting antimicrobial-resistant uropathogens that cause urinary tract infections. The project addresses escalating antimicrobial resistance in uropathogenic Escherichia coli, the leading cause of UTIs...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $262,388 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the RNA binding protein HNRNPA2B1 regulates macrophage responses to Mycobacterium tuberculosis infection. The research examines alternative splicing as a mechanism controlling the balance between MTB virulence and host antimicrobial defenses. The award funds work to define how...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arkansas for Medical Sciences $447,720 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and employ innovative in vitro and in vivo platforms for studying Acinetobacter baumannii ventilator-associated pneumonia (VAP) pathogenesis and prevention strategies. The research addresses a critical gap in VAP science: A. baumannii causes approximately 30 percent of...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University $140,496 on January 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of cytochrome BD in supporting flagellar motility in uropathogenic Escherichia coli. The research elucidates connections between bacterial aerobic respiration and flagellar motility in UPEC, the primary cause of urinary tract infections, with the goal of identifying pathways essential...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded New York University School of Medicine $254,250 on May 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of lung microbiome sulfur metabolism in oxidative stress and inflammatory airway disease. The recipient will assess whether altered sulfur metabolism associated with enrichment of...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $481,250 on April 1, 2026, to develop and test inhibitors of the reverse transsulfuration pathway as a novel treatment for Helicobacter pylori infection under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research evaluates aminooxyacetic acid (AOAA) and propargylglycine (PAG)—compounds initially developed to inhibit mammalian reverse transsulfuration pathway...
- The National Institute of Allergy and Infectious Diseases awarded New York University $742,364 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate autolysin control pathways in Pseudomonas aeruginosa. The research examines how bacteria regulate cell wall-degrading enzymes (autolysins) to control their activity during cell growth and division. Pseudomonas aeruginosa serves as the model organism because it causes serious human infections...